Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ASAH1 | Q13510 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALPG | P10696 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16366709 | 0.82 | TMEM97 (0.54) | LMNATDP1CYP3A4HPGDHSD17B10 | |
| SCHEMBL17830757 | 0.80 | TDP1 (0.54) | LMNATDP1CYP3A4HPGDHSD17B10 | |
| SCHEMBL14044191 | 0.77 | LMNA (0.59) | LMNATDP1CYP3A4HPGDHSD17B10 | |
| SCHEMBL4420231 | 0.73 | LMNA (0.70) | LMNATDP1CYP3A4HPGDHSD17B10 | |
| SCHEMBL4423635 | 0.71 | TP53 (0.63) | LMNATDP1CYP3A4HPGDHSD17B10 | |
| SCHEMBL10987080 | 0.71 | TDP1 (0.55) | LMNATDP1CYP3A4HPGDHSD17B10 | |
| SCHEMBL22819341 | 0.71 | P2RX3 (0.54) | LMNATDP1CYP3A4HPGDHSD17B10 | |
| SCHEMBL17830731 | 0.69 | LMNA (0.61) | LMNATDP1CYP3A4HPGDHSD17B10 | |
| SCHEMBL8136668 | 0.69 | TP53 (0.68) | LMNAHPGDTP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL22802595 | 0.68 | TDP1 (0.49) | LMNATDP1CYP3A4HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016094226-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREGIMMUNE, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | LMNA 2135/4885TDP1 3582/4885CYP3A4 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.